Prognostic value of 18F-FDG PET/MR imaging biomarkers in oesophageal squamous cell carcinoma

Yu, Chih‐Wei; Chen, Xin-Jia; Lin, Yen‐Heng; Tseng, Yao-Hui; Lu, Ching‐Chu; Chen, Bang-Bin; Wei, Shih-Chung; Lee, Jang-Ming; Shih, Tiffany Ting-Fang

doi:10.1016/j.ejrad.2019.108671

Cited by 10 publications

(9 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our findings are consistent with those of several previous studies ( 21 ), but some studies have found significant differences in ADC and MTV between high and low T-stage tumors ( 22 ), and some studies involving PET/CT have reported a significant correlation between tumor SUV max and N stage ( 23 ). In the present study, we found that the SUV max and D max of lymph nodes may be useful in differentiating metastatic and non-metastatic lymph nodes.…”

Section: Discussionsupporting

confidence: 93%

Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT

Wang

Guo²,

Zhang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

ObjectivesTo investigate the value of 18F-FDG PET/MRI in the preoperative assessment of esophageal squamous cell carcinoma (ESCC) and compare it with 18F-FDG PET/CT, MRI, and CECT.MethodsThirty-five patients with resectable ESCC were prospectively enrolled and underwent PET/MRI, PET/CT, and CECT before surgery. The primary tumor and regional lymph nodes were assessed by PET/MRI, PET/CT, MRI, and CECT, respectively, and the diagnostic efficiencies were determined with postoperative pathology as a reference standard. The predictive role of imaging and clinical parameters on pathological staging was analyzed.ResultsFor primary tumor staging, the accuracy of PET/MRI, MRI, and CECT was 85.7%, 77.1%, and 51.4%, respectively. For lymph node assessment, the accuracy of PET/MRI, PET/CT, MRI, and CECT was 96.2%, 92.0%, 86.8%, and 86.3%, respectively, and the AUCs were 0.883, 0.745, 0.697, and 0.580, respectively. PET/MRI diagnosed 13, 7, and 6 more stations of lymph node metastases than CECT, MRI, and PET/CT, respectively. There was a significant difference in SUVmax, TLG, and tumor wall thickness between T1-2 and T3 tumors (p = 0.004, 0.024, and < 0.001, respectively). Multivariate analysis showed that thicker tumor wall thickness was a predictor of a higher T stage (p = 0.040, OR = 1.6).Conclusions18F-FDG PET/MRI has advantages over 18F-FDG PET/CT, MRI, and CECT in the preoperative assessment of primary tumors and regional lymph nodes of ESCC. 18F-FDG PET/MRI may be a potential supplement or alternative imaging method for preoperative staging of ESCC.

show abstract

Section: Discussionsupporting

confidence: 93%

Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT

Wang

Guo²,

Zhang³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Similar to our findings, previous studies also found no significant correlations between pretreatment SUVs and ADCs ( 30 – 32 ). Our results also revealed that pretreatment SUVs, MTV, and TLG were significantly higher in tumor stage ≥ T 3 than in tumor stage < T 2 , while ADC min values has not yet been found to correlate with the clinical T-stage, indicating the effect of tumor load on 18 F-FDG metabolism, consistent with the literature ( 8 , 33 ). These results suggest that enhanced glucose metabolism as measured on FDG PET and restricted water diffusion as measured using ADC represent independent biological properties and refer to different aspects of tumor pathophysiology.…”

Section: Discussionsupporting

confidence: 91%

“…Currently, metabolic and functional imaging modalities such as 18 F-fluorodeoxyglucose positron emission tomography–computed tomography ( 18 F-FDG PET-CT) and diffusion-weighted magnetic resonance imaging (DW-MRI) are gaining increasing clinical significance in the management of patients undergoing radiotherapy since these allow visualization and quantification of treatment-induced changes on a molecular level before volumetric changes become apparent ( 6 – 8 ). It is well known that PET-based parameters such as standardized uptake value (SUV), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) have been established and validated as prognostic biomarkers in EC ( 8 , 9 ). Escalating the radiation dose to 64.8 Gy, which had been previously established, failed to improve survival or locoregional control ( 10 ).…”

Section: Introductionmentioning

confidence: 99%

Geometrical Comparison and Quantitative Evaluation of 18F-FDG PET/CT- and DW-MRI-Based Target Delineation Before and During Radiotherapy for Esophageal Squamous Carcinoma

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Background and PurposeThis study aimed to evaluate the geometrical differences in and metabolic parameters of 18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET-CT) and diffusion-weighted magnetic resonance imaging (DW-MRI) performed before and during radiotherapy (RT) for patients with esophageal cancer based on the three-dimensional CT (3DCT) medium and explore whether the high signal area derived from DW-MRI can be used as a tool for an individualized definition of the volume in need of dose escalation for esophageal squamous cancer.Materials and MethodsThirty-two patients with esophageal squamous cancer sequentially underwent repeated 3DCT, 18F-FDG PET-CT, and enhanced MRI before the initiation of RT and after the 15th fraction. All images were fused with 3DCT images through deformable registration. The gross tumor volume (GTV) was delineated based on PET Edge on the first and second PET-CT images and defined as GTVPETpre and GTVPETdur, respectively. GTVDWIpre and GTVDWIdur were delineated on the first and second DWI and corresponding T2-weighted MRI (T2W-MRI)-fused images. The maximum, mean, and peak standardized uptake values (SUVs; SUVmax, SUVmean, and SUVpeak, respectively); metabolic tumor volume (MTV); and total lesion glycolysis(TLG) and its relative changes were calculated automatically on PET. Similarly, the minimum and mean apparent diffusion coefficient (ADC; ADCmin and ADCmean) and its relative changes were measured manually using ADC maps.ResultsThe volume of GTVCT exhibited a significant positive correlation with that of GTVPET and GTVDWI (both p < 0.001). Significant differences were observed in both ADCs and 18F-FDG PET metabolic parameters before and during RT (both p < 0.001). No significant correlation was observed between SUVs and ADCs before and during RT (p = 0.072–0.944) and between ∆ADCs and ∆SUVs (p = 0.238–0.854). The conformity index and degree of inclusion of GTVPETpre to GTVDWIpre were significantly higher than those of GTVPETdur to GTVDWIdur (both p < 0.001). The maximum diameter shrinkage rate (∆LDDWI) (24%) and the tumor volume shrinkage rate (VRRDWI) (60%) based on DW-MRI during RT were significantly greater than the corresponding PET-based ∆LDPET (14%) and VRRPET (41%) rates (p = 0.017 and 0.000, respectively).ConclusionBased on the medium of CT images, there are significant differences in spatial position, biometabolic characteristics, and the tumor shrinkage rate for GTVs derived from 18F-FDG PET-CT and DW-MRI before and during RT for esophageal squamous cancer. Further studies are needed to determine if DW-MRI will be used as tool for an individualized definition of the volume in need of dose escalation.

show abstract

“…The minimum ADC value exhibited the strongest inverse correlation with SUVs and was lower in higher T-stage tumors. Volume based parameters can also be calculated and include total lesion glycolysis and metabolic tumor volume, which were more accurate at predicting T-and N-stage respectively, than were ADC values (54).…”

Section: Pet/mrmentioning

confidence: 99%

New frontiers in esophageal radiology

Schmidlin¹,

Gill²

2021

Ann Transl Med

View full text Add to dashboard Cite

Esophageal cancer is the sixth most common cause of cancer related mortality worldwide.Advances in treatment have translated into steadily improving survival rates. Accurate preoperative staging of esophageal cancer is imperative in order to provide an accurate prognosis and direct patients to the most appropriate treatment. Current preoperative staging relies on imaging, most commonly endoscopic ultrasound (EUS), computed tomography (CT) and positron emission tomography (PET). A combination of these modalities should be used in preoperative staging, as each has advantages over another. Magnetic resonance imaging (MRI) has always shown promise in its ability to accurately stage esophageal cancer, though it has not been consistently adopted as a common tool for this purpose. Recent research has demonstrated that MRI can become an integral part of esophageal cancer clinical staging. Advances in MR technology that utilize radial sampling allow for shorter, free breathing techniques without degradation of image quality, resulting in improved capability for T and N staging of esophageal cancer. MRI enhanced with superparamagnetic iron oxide (SPIO) and ultrasmall SPIO (USPIO) nanoparticles has been shown to be useful for the detection of metastatic disease in lymph nodes. This article will review the current evidence in the role that imaging plays in staging esophageal cancer.

show abstract

Prognostic value of 18F-FDG PET/MR imaging biomarkers in oesophageal squamous cell carcinoma

Cited by 10 publications

References 34 publications

Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT

Value of 18F-FDG PET/MRI in the Preoperative Assessment of Resectable Esophageal Squamous Cell Carcinoma: A Comparison With 18F-FDG PET/CT, MRI, and Contrast-Enhanced CT

Geometrical Comparison and Quantitative Evaluation of 18F-FDG PET/CT- and DW-MRI-Based Target Delineation Before and During Radiotherapy for Esophageal Squamous Carcinoma

New frontiers in esophageal radiology

Contact Info

Product

Resources

About